帕博利珠单抗联合每周大分割放疗治疗膀胱癌的剂量限制性泌尿系统毒性
PLUMMB试验(NCT02560636)是一项Ⅰ期研究,评估帕博利珠单抗联合每周放疗治疗转移性或局部晚期膀胱尿路上皮癌的耐受性。首个剂量队列中,患者每3周接受帕博利珠单抗100 mg,并在开始每周自适应膀胱放疗(36 Gy分6次)前2周开始用药;5例患者后该队列因达到预设剂量限制性毒性定义而停止。3例发生3级泌尿系统毒性(其中2例归因于治疗),1例发生4级直肠穿孔;试验已暂停,方案将修订以降低每次放疗剂量。
要点
- 首个剂量队列5例中3例发生3级泌尿系统毒性,2例归因于治疗。
- 1例发生4级直肠穿孔,试验因此暂停并将修订方案。
- 作者提醒联合放疗与免疫检查点时需谨慎,尤其是盆腔肿瘤高剂量分割放疗。
核心结论
- PLUMMB试验首个剂量队列达到方案预设的剂量限制性毒性定义,试验已暂停,方案将修订以降低每次放疗剂量。
- 作者提醒联合放疗与免疫检查点阻断时需谨慎,尤其是盆腔肿瘤采用高剂量分割放疗时。
研究设计与样本
- PLUMMB试验(NCT02560636)是一项Ⅰ期研究,评估每周放疗联合帕博利珠单抗治疗转移性或局部晚期膀胱尿路上皮癌的耐受性。
- 首个剂量队列患者接受帕博利珠单抗100 mg每3周一次,于开始每周自适应膀胱放疗前2周开始给药。
- 放疗剂量为36 Gy分6次。
主要发现
- 首个剂量队列在5例患者后停止,因达到预设的剂量限制性毒性定义。
- 3例患者发生3级泌尿系统毒性,其中2例归因于治疗。
- 1例患者发生4级直肠穿孔。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
There is currently significant interest in the potential benefits of combining radiation and immune checkpoint blockade (ICB) to stimulate both regional and distant abscopal immune responses. In melanoma and lung cancer, patients who have received radiation therapy during ICB appear to have prolonged survival. The PLUMMB trial (Pembrolizumab in Muscle-invasive/Metastatic Bladder cancer) (NCT02560636) is a phase I study to test the tolerability of a combination of weekly radiation therapy with pembrolizumab in patients with metastatic or locally advanced urothelial cancer of the bladder. In the first dose-cohort, patients received pembrolizumab 100 mg 3-weekly, starting 2 weeks before commencing weekly adaptive bladder radiation therapy to a dose of 36 Gy in 6 fractions. The first dose-cohort was stopped after 5 patients, having met the predefined definition of dose-limiting toxicity. Three patients experienced grade 3 urinary toxicities, 2 of which were attributable to therapy. One patient experienced a grade 4 rectal perforation. In view of these findings, the trial has been paused and the protocol will be amended to reduce radiation therapy dose per fraction. The authors advise caution to those combining radiation therapy and ICB, particularly when radiation therapy is given at high dose per fraction for pelvic tumours. The PLUMMB trial met the protocol-defined definition of dose-limiting toxicity and will be amended to reduce radiation therapy dose.
引用
- Tree AC, Jones K, Hafeez S, et al. Dose-limiting Urinary Toxicity With Pembrolizumab Combined With Weekly Hypofractionated Radiation Therapy in Bladder Cancer. Int J Radiat Oncol Biol Phys. 2018. PMID: 30012528. doi:10.1016/j.ijrobp.2018.04.070
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。